Omacor® is a highly purified and highly concentrated preparation of omega-3 polyunsaturated fatty acids. Solvay Pharmaceuticals licensed it in from Pronova Biocare in Norway, for marketing in a territory of 57 countries worldwide.

Omacor® is used in combination with other medicines, for treatment after a heart attack (Myocardial Infarction, MI) to reduce the risk of further heart attacks and improve overall survival. It is also prescribed for the treatment of high blood triglyceride levels when changes to the diet have been insufficient.

In a large mortality trial involving more than 11,000 post-MI patients, Omacor® has been shown to significantly reduce overall mortality by 20%, cardiovascular mortality by 30% and sudden death by 45%. The product has thus proven to save lives of post-MI patients when added to standard therapy available so far.

Omacor® has already been introduced to several European markets, and launches in the other territories are expected to commence soon.